31 January 2019
Visiongain has launched a new pharma report Pharma Leader Series: Top Generic Drug Producers Market Forecast 2019-2029: North America, Europe, India, Rest of the World (RoW).
This report ranks the world’s top 50 generic drug manufacturers according to their generic drug revenues in 2017. It analyses the leading companies operating in the generic drug market and discusses forces that shape companies’ strategic directions. There have been a number of consolidation activities, mergers, acquisitions and divestitures occurring amongst the leading players in the generic drugs market over the last few years. This level of corporate activities has led to the creation of a market which is steep in growth opportunities for companies that are able to align their strategies to growth.
The lead analyst of the report commented "Related to the move towards biosimilars and the decreasing distance between originator and generic companies is the rise of the complex generics sector. As generics competition steadily increases in all markets, there are strong incentives for companies with sufficiently advanced technologies to move beyond simple generics into more complex, higher-margin products.
With differentiation likely to increase in importance as the generics market becomes more competitive, novel delivery systems and reformulations (for example, extended-release versions of original products) will also increase in significance for generics companies. Competitive strength in this field will require investment in ongoing R&D, further contributing to the closure of the gap between original and generic manufacturers."
Leading companies featured in the report include Abbott, Aurobindo, EMS, Endo, Fresenius, Kabi, Mylan, Novartis (Sandoz), Pfizer, Sun Pharmaceuticals, Teva.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
For the companies operating in the global influenza vaccines market, there is an immense opportunity from emerging economies across the globe.
30 September 2020
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical companies. New market dynamics including an evolving product line, more stringent regulations, geographically connected supply chains, rising risk, and extreme cost pressure have raised stakes significantly.
28 September 2020
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.